An Open Label, Prospective, Randomized, Multicenter Study Investigating Clinical Efficacy and Safety of the Human Normal Immunoglobulin for Intravenous Administration BT595 in Patients With Chronic Primary Immune Thrombocytopenia (ITP)
Latest Information Update: 20 Apr 2023
At a glance
- Drugs Immune globulin (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Registrational; Therapeutic Use
- Sponsors Biotest AG; Biotest Pharmaceuticals
- 01 Apr 2023 Results assessing the efficacy and safety of the new 10% human intravenous immunoglobulin BT595 in adult patients with chronic immune thrombocytopenia, published in the Transfusion Medicine.
- 12 Aug 2019 Status changed from recruiting to completed.
- 17 Mar 2019 This trial has been completed in Germany, according to European Clinical Trials Database